Sort By:
Date
Title
Category:

Paula Salmikangas presents on Regulatory and scientific challenges for global development

NDAs Dr Paula Salmikangas has been invited to present at the World Advanced Therapies and Regenerative Medicine Congress.

| Community News, Homepage News, News, Services News, Social News

Free Webinar - Rational EU risk management for oncology medicines: time for a rethink

Join us on Thursday, 24th May to learn how you can implement the revised GVP module (V) concerning risk management in the interests of patients throughout the life-cycle of a medicine.

| Community News, Homepage News, News, Services News, Social News

Professor Carole Longson to join NDA as Scientific Adviser

We are pleased to announce that Professor Carole Longson has joined the NDA Advisory Board.

| Community News, Homepage News, News, Services News, Social News

Is a global regulatory and market access strategy the way to go?

Dr. Thomas Lönngren, Strategic Advisor NDA Group and former Executive Director EMA, has been invited to present at the Chief Medical Officer Summit in Boston May 7th.

| Community News, Homepage News, News, Services News, Social News

Seeking Parallel Consultation

Learn about the rationales and results of engaging early with regulators and HTA bodies in this white paper written by NDAs Dr. Mira Pavlovic-Ganascia and Claes Buxfeldt.

| Articles, Community News, Health Technology Assessment, Homepage News, News, Services News, Social News

Immunogenicity for investigational biopharmaceutical products - Start with the goal in mind

NDA invites to breakfast seminar where Paul Chamberlain speaks on anticipating and avoiding issues for biopharmaceutical development.

| Community News, News, Social News

Europe vs USA: new drug product approvals in 2017

What are the key differences in new drug product approvals across the US and EU regions? Learn about the state of drug approvals in the world's two largest markets.

| Articles, Community News, Homepage News, News, Presentations and Infographics, Services News, Social News

Join us on a 3 day Course, learn about the Development of Biological Drugs

On the 28th - 30th May, NDA will contribute to a 3 day Course in the Development of Biological Drugs in Stockholm and/or distance.

| Community News, News, Presentations and Infographics, Services News, Social News

Meet NDA at DIA Europe 2018

Don’t miss the opportunity to meet our Experts who will present on a number of critical drug development topics and be on hand to answer your questions.

| Community News, News, Presentations and Infographics, Social News

NDA Group to open a new office in Paris

To serve our increasing French customer base and in continuation of our strategic global expansion we are delighted to announce the opening of our new Paris office.

| Community News, News, Services News, Social News

Claes Buxfeldt joins NDA Group as new HTA Director

Claes brings with him a wealth of knowledge and experience from his time in industry. For clients leading drug development consultancy this means faster provision of market access enabling advice and support.

| Community News, News, Services News, Social News

NDA Group celebrates 20 years of championing treatments for rare diseases

Over the years NDA has been involved in the development of more than 50 products for individuals with rare diseases.

| Community News, News, Services News, Social News

Senior Consultant, US West Coast

Are you an experienced specialist in regulatory affairs within drug development? Become a part of NDA’s growing, highly qualified team!

| Community News, News, Services News, Social News

NDA Group welcomes proposal for new HTA regulation in Europe

The particular focus on Relative Effectiveness Assessment, the establishment of a new Coordination Group of clinical experts from the Member States and the continuation of the practices established by the voluntary European HTA network were all cited as reasons for a promising future for the regulation.

| Community News, Health Technology Assessment, News, Services News

Andrew Monaghan joins NDA Group as UK General Manager

Andrew brings over 35 years’ of experience in the drug development industry to the well-established UK team of close to 50 consultants and support staff.

| Community News, News, Services News

NDA Intelligence

Subscribe to the latest intelligence from the true thought leaders in the field and access it at any time.

Sign In

Create Account

By signing up you are agreeing to our terms of service